Reltio, a cloud-native master data management software provider, has introduced Reltio Enterprise 360 Site Intelligence. The software centralizes detailed data about study sites and principal investigators. Features include the ability to search all current, complete, accurate information available on healthcare organizations/ study sites, and HCP/PIs; evaluate and rate study sites and principal investigators using artificial intelligence (AI), quantitative metrics, and qualitative criteria, and manage consent, contracting, and collaboration workflows.
For more information, click here.
Tecentriq Falls Short in Phase III Trial in Post-Surgery Triple-Negative Breast Cancer Patients
February 6th 2025In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative breast cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.